title: CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
abstract: OBJECTIVE
  Currently, there is no clinically validated test for the prediction of response to tubulin-targeting agents in non-small cell lung cancer (NSCLC). Here, we investigated the significance of nuclear expression of the mitotic checkpoint gene checkpoint with forkhead and ringfinger domains (CHFR) as predictor of response and overall survival with taxane-based first-line chemotherapy in advanced stage NSCLC.
  
  
  METHODS
  We studied a cohort of 41 patients (median age 63 years) with advanced NSCLC treated at the Atlanta VAMC between 1999 and 2010. CHFR expression by immunohistochemistry (score 0-4) was correlated with clinical outcome using chi-square test and Cox proportional models. A cutoff score of "3" was determined by receiver operator characteristics analysis for "low" CHFR expression. Results were validated in an additional 20 patients who received taxane-based chemotherapy at Emory University Hospital and the Atlanta VAMC.
  
  
  RESULTS
  High expression (score = 4) of CHFR is strongly associated with adverse outcomes: the risk for progressive disease after first-line chemotherapy with carboplatin-paclitaxel was 52% in patients with CHFR-high versus only 19% in those with CHFR-low tumors (P = 0.033). Median overall survival was strongly correlated with CHFR expression status (CHFR low: 9.9 months; CHFR high: 6.2 months; P = 0.002). After multivariate adjustment, reduced CHFR expression remained a powerful predictor of improved overall survival (HR = 0.24; 95% CI, 0.1-0.58%; P = 0.002). In the validation set, low CHFR expression was associated with higher likelihood of clinical benefit (P = 0.03) and improved overall survival (P = 0.038).
  
  
  CONCLUSIONS
  CHFR expression is a novel predictive marker of response and overall survival in NSCLC patients treated with taxane-containing chemotherapy.
authors: Department of Hematology and Oncology, Emory University, Atlanta, Georgia 30322, USA.
authors: Rathi N
authors: RN
authors: Pillai
authors: Seth A
authors: SA
authors: Brodie
authors: Gabriel L
authors: GL
authors: Sica
authors: You
authors: Y
authors: Shaojin
authors: Ge
authors: G
authors: Li
authors: Dana C
authors: DC
authors: Nickleach
authors: Liu
authors: L
authors: Yuan
authors: Vijay A
authors: VA
authors: Varma
authors: Dacian
authors: D
authors: Bonta
authors: James G
authors: JG
authors: Herman
authors: Malcom V
authors: MV
authors: Brock
authors: Maria J A
authors: MJ
authors: Ribeiro
authors: Suresh S
authors: SS
authors: Ramalingam
authors: Taofeek K
authors: TK
authors: Owonikoko
authors: Fadlo R
authors: FR
authors: Khuri
authors: Johann C
authors: JC
authors: Brandes
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics; D001952:Bridged-Ring Compounds / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D018797:Cell Cycle Proteins / Q000235:genetics*; D019175:DNA Methylation / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D009363:Neoplasm Proteins / Q000235:genetics*; D000075223:Poly-ADP-Ribose Binding Proteins; D011379:Prognosis; D043823:Taxoids / Q000008:administration & dosage*; D044767:Ubiquitin-Protein Ligases
chemical_list: D014408:Biomarkers, Tumor; D001952:Bridged-Ring Compounds; D018797:Cell Cycle Proteins; D009363:Neoplasm Proteins; D000075223:Poly-ADP-Ribose Binding Proteins; D043823:Taxoids; C080625:taxane; C412002:CHFR protein, human; D044767:Ubiquitin-Protein Ligases
references: N Engl J Med. 2009 Sep 3;361(10):947-57
references: 19692680
references: N Engl J Med. 2006 Dec 14;355(24):2542-50
references: 17167137
references: Oncogene. 2002 Apr 4;21(15):2328-33
references: 11948416
references: N Engl J Med. 2002 Jan 10;346(2):92-8
references: 11784875
references: Clin Cancer Res. 2002 Jul;8(7):2286-91
references: 12114432
references: Int J Cancer. 2011 Mar 1;128(5):1009-17
references: 20473935
references: Carcinogenesis. 2003 Jan;24(1):47-51
references: 12538348
references: J Clin Oncol. 2007 Jul 1;25(19):2741-6
references: 17602079
references: Cancer Biol Ther. 2005 Jul;4(7):773-80
references: 16123600
references: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references: 18287387
references: N Engl J Med. 2007 Feb 22;356(8):800-8
references: 17314339
references: Int J Oncol. 2007 Oct;31(4):713-20
references: 17786301
references: Carcinogenesis. 2005 Jun;26(6):1152-6
references: 15760919
references: J Clin Oncol. 2007 Jul 1;25(19):2747-54
references: 17602080
references: Cancer Res. 2003 Dec 15;63(24):8606-13
references: 14695171
references: Int J Cancer. 2010 Feb 1;126(3):743-55
references: 19621389
references: Oncogene. 2005 Apr 14;24(16):2589-98
references: 15674323
references: Lancet Oncol. 2013 Jan;14(1):38-47
references: 23200175
references: Cancer Res. 2002 Mar 15;62(6):1797-801
references: 11912157
references: Mol Cancer. 2006 Feb 20;5:8
references: 16504004
references: J Biol Chem. 2012 Apr 13;287(16):12975-84
references: 22337872
references: Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7818-23
references: 12810945
references: N Engl J Med. 2006 Sep 7;355(10):983-91
references: 16957145
references: J Gastroenterol. 2006 Feb;41(2):133-9
references: 16568372
references: Mod Pathol. 2006 Apr;19(4):524-32
references: 16554732
references: J Cell Biol. 2002 Jan 21;156(2):249-59
references: 11807090
references: J Clin Oncol. 2004 May 15;22(10):1966-74
references: 15111619
references: Nature. 2008 Jan 3;451(7174):81-5
references: 18172500
references: Nat Genet. 2005 Apr;37(4):401-6
references: 15793587
references: Clin Gastroenterol Hepatol. 2006 Jun;4(6):701-8
references: 16678495
references: Int J Cancer. 2008 Oct 1;123(7):1623-30
references: 18623126
references: N Engl J Med. 2010 Oct 28;363(18):1693-703
references: 20979469
references: J Clin Oncol. 2004 May 1;22(9):1589-97
references: 15117980
references: Nature. 2000 Jul 27;406(6794):430-5
references: 10935642
references: Cancer Res. 2003 Nov 1;63(21):7185-9
references: 14612512
references: Lung Cancer. 2011 Apr;72(1):84-91
references: 20705357